OLX01 is a first-in-class oncology therapy targeting cancer cell metabolism…
MOA – First-in-class drug targeting cancer cell metabolism
Safe – Safely tested in over 1,200 patients worldwide with no serious drug-related side effects
Efficacious – Demonstrates immediate apoptosis-mediated cell death of cancers cells
Cost Effective – 28 dose cycle is projected to be at $8,400
OLX01: In Vitro Data
How will we scale in the future
Compared OLX01 to one of the leading chemotherapies, Carboplatin (10 ug/mL).
OLX01 demonstrated complete inhibition of cellular proliferation of human cancer cell lines and were statistically more effective than carboplatin (10 ug/mL highest dose) at killing cancer cells.
Cell Proliferation Assay
OLX01: Phase I Clinical Study Results
No Issues in Human Dosing
Phase I safety study in healthy human subjects (N = 37; five dosing cohorts and one elderly cohort) demonstrated no adverse effects through the maximum dose of 0.7 mL/kg (2.8 times planned clinical dose).
Blood parameters demonstrate OLX01 is enhancing oxygenation, reducing ROS and enhancing perfusion…. all surrogates of metabolic stabilization.